Pyrazinamide is the TB Medication That Increases Uric Acid
Pyrazinamide (PZA) is the anti-tubercular drug that commonly raises serum uric acid levels, with hyperuricemia occurring in 82-85% of patients receiving this medication 1, 2.
Mechanism and Clinical Significance
Pyrazinamide causes hyperuricemia primarily by decreasing uric acid clearance rather than increasing production. Studies demonstrate that uric acid clearance drops significantly (from 8.77 to 3.50 mL/min per 1.73 m²) within two weeks of starting PZA, while serum uric acid levels rise dramatically (from 4.44 to 9.78 mg/dL) 3. This effect is:
- Reversible: Uric acid levels return to baseline after PZA is discontinued (typically after the 2-month intensive phase) 3
- Expected and generally benign: Guidelines explicitly state that "modest elevated serum uric acid levels are also expected, although the clinical significance of this is unclear" 1
- Not an indication to stop treatment: "Isolated increases in uric acid without symptoms of gout are common and are not an indication to discontinue the drug" 1
Clinical Management Algorithm
When to Monitor
- Baseline uric acid measurement is not routinely recommended but may serve as a surrogate marker for compliance 4
- Monitor only if patient develops symptoms or has pre-existing gout
When to Treat Hyperuricemia
Do NOT treat asymptomatic hyperuricemia - it requires no intervention 4, 2
DO treat if:
- Patient develops symptomatic arthralgia (occurs in only 4-25% of patients) 5, 2, 6
- Patient has history of gout (PZA is generally contraindicated in this population) 4
- Acute gouty arthritis develops (rare except in those with pre-existing gout) 4
Treatment Approach
When symptomatic:
- Uric acid-lowering medications were needed in only 9-23% of patients 2
- Continue PZA unless severe symptoms develop
- In the study of 226 patients, no patient required PZA discontinuation due to hyperuricemia alone 2
Important Caveats
Risk factors for symptomatic hyperuricemia include:
- Male sex (higher rates of both hyperuricemia and arthralgia) 6
- Pre-existing gout 4
- Renal insufficiency (increases risk substantially) 4
- Hypertension, heart failure, chronic kidney disease 7
Ethambutol also contributes minimally to uric acid elevation but is far less significant than pyrazinamide 7, 3.
Clinical pearl: Paradoxically, hyperuricemia during TB treatment may indicate better adherence and outcomes, as it serves as a biomarker of consistent medication use 8.